Fesoterodine

Drug Profile

Fesoterodine

Alternative Names: Fesosterodine; Fesoterodine fumarate; PF-00695838; SPM 007; SPM 907; Toviaz

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schwarz Pharma
  • Developer Pfizer
  • Class Antispasmodics; Benzhydryl compounds; Esters; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Stress incontinence

Most Recent Events

  • 31 Jul 2017 Fesoterodine is still in phase III trials for Overactive bladder (in adolescents, in children) in countries worldwide (PO) (NCT01557244)
  • 21 Jul 2016 Biomarkers information updated
  • 01 Jun 2015 Pfizer initiates enrolment in a phase III trial for Overactive bladder (In children, In adolescents) in Japan (NCT02501928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top